Expedeon AG

    Expedeon (Frankfurt, PRIME: EXN) is an enabler of advances in medical science and patient care. The company’s core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. For H1 2018, Expedeon reported a continued strong revenue growth and a positive EBITDA and expects an overall positive EBITDA for the fi nancial year 2018. The change of the company name to Expedeon AG from SYGNIS AG completed in August 2018 reflects the unified global positioning and the new corporate branding after the successful integration of the recently acquired companies.


    Overview:

    Field of Activity Expedeon offers a wide range of products covering workflows across genomics, proteomics and immunology research. The company’s innovative technologies are also licensed for commercial use in POC & clinical diagnostic such as ELISA, lateral flow and NGS based liquid biopsy applications.
    Ownership Structure and Financing Investors 15%, Management 3%, Freefl oat 82%. GBP 5 million debt financing secured in August 2018; giving access to alternative nondilutive means to finance rapid growth plans.
    Partners Extensive OEM, supply and licensing agreements with partners in the life science industry worldwide, including PerkinElmer, Merck, US Biological, Abingdon Health and TANON.
    Products / Services Innovative, enabling, easy-to-use, robust and reliable technologies, products and custom services for life science research and diagnostic product development including NGS based liquid biopsy, whole genome amplification, antibody- and protein-labelling, and immunoassay development.
    Unique Selling Point Enabling and scalable technologies delivered as high quality reliable products or services. We are constantly pushing the boundaries to provide high quality, easy-to use, cost-effective solutions which enable our customers to progress their research, drug discovery or diagnostic product development programs.
    Technology Key technologies include TruePrime™ for DNA amplification, Lightning-Link® for antibody labelling, CaptSure™ for antibody capture, RunBlue™ for protein analysis.
    Date of Incorporation 2013
    Number of Employees 105


     Contact:

    Telephone +49 6221 3540-125
    Telefax +49 6221 3540-127
    E-Mail info@expedeon.com

    Address:

    Expedeon AG
    Waldhofer Str. 102
    69123 Heidelberg

    Social Media:
    Twitter | LinkedIn

    ANZEIGE

    Website:

    www.expedeon.com
    www.investors.expedeon.com


     

    Print Friendly, PDF & Email